Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.

Siri Lagethon Heck,Albulena Mecinaj,Anne Hansen Ree,Pavel Hoffmann,Jeanette Schulz-Menger,Morten W. Fagerland,Berit Gravdehaug,Helge Røsjø,Kjetil Steine,Jürgen Geisler,Geeta Gulati,Torbjørn Omland

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.

2021

Siri Lagethon Heck
Albulena Mecinaj
Anne Hansen Ree
Pavel Hoffmann
Jeanette Schulz-Menger
Morten W. Fagerland
Berit Gravdehaug
Helge Røsjø
Kjetil Steine
Jürgen Geisler
Geeta Gulati
Torbjørn Omland

Background: Adjuvant breast cancer therapy containing anthracyclines with or without anti–human epidermal growth factor receptor–2 antibodies and radiotherapy is associated with cancer treatment–re...

Keywords:

Breast cancer
Candesartan
Beta blocker
Urology
Clinical trial
Cardiac magnetic resonance imaging
Cardiomyopathy
Placebo
Metoprolol
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations